Sonova Holding AG

SWX:SOON Stock Report

Market Cap: CHF 17.9b

Sonova Holding Valuation

Is SOON undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SOON when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SOON (CHF300.4) is trading below our estimate of fair value (CHF365.41)

Significantly Below Fair Value: SOON is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SOON?

Key metric: As SOON is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SOON. This is calculated by dividing SOON's market cap by their current earnings.
What is SOON's PE Ratio?
PE Ratio29.8x
EarningsCHF 601.00m
Market CapCHF 17.91b

Price to Earnings Ratio vs Peers

How does SOON's PE Ratio compare to its peers?

The above table shows the PE ratio for SOON vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average65.7x
STMN Straumann Holding
61.4x20.9%CHF 17.7b
MOVE Medacta Group
42.1x18.4%CHF 2.2b
MED Medartis Holding
151.9x51.7%CHF 612.5m
METN Metall Zug
7.5x-29.6%CHF 510.8m
SOON Sonova Holding
29.8x8.8%CHF 17.9b

Price-To-Earnings vs Peers: SOON is good value based on its Price-To-Earnings Ratio (29.8x) compared to the peer average (65.7x).

Price to Earnings Ratio vs Industry

How does SOON's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
SOON 29.8xIndustry Avg. 28.9xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SOON is expensive based on its Price-To-Earnings Ratio (29.8x) compared to the European Medical Equipment industry average (28.9x).

Price to Earnings Ratio vs Fair Ratio

What is SOON's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SOON PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio29.8x
Fair PE Ratio33.3x

Price-To-Earnings vs Fair Ratio: SOON is good value based on its Price-To-Earnings Ratio (29.8x) compared to the estimated Fair Price-To-Earnings Ratio (33.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SOON forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 300.40
CHF 296.39
-1.3%
13.2%CHF 375.00CHF 227.00n/a18
Nov ’25CHF 320.80
CHF 292.78
-8.7%
12.4%CHF 350.00CHF 227.00n/a18
Oct ’25CHF 301.10
CHF 287.53
-4.5%
11.3%CHF 345.00CHF 227.00n/a17
Sep ’25CHF 295.80
CHF 286.06
-3.3%
11.0%CHF 335.00CHF 227.00n/a17
Aug ’25CHF 269.30
CHF 284.82
+5.8%
11.8%CHF 335.00CHF 220.00n/a17
Jul ’25CHF 280.30
CHF 284.82
+1.6%
11.8%CHF 335.00CHF 220.00n/a17
Jun ’25CHF 284.80
CHF 279.12
-2.0%
12.6%CHF 335.00CHF 220.00n/a17
May ’25CHF 255.40
CHF 270.29
+5.8%
11.4%CHF 325.00CHF 200.00n/a17
Apr ’25CHF 261.10
CHF 270.65
+3.7%
12.0%CHF 325.00CHF 200.00n/a17
Mar ’25CHF 276.50
CHF 270.59
-2.1%
13.4%CHF 325.00CHF 200.00n/a17
Feb ’25CHF 279.10
CHF 267.06
-4.3%
14.7%CHF 325.00CHF 200.00n/a16
Jan ’25CHF 274.40
CHF 257.07
-6.3%
12.7%CHF 320.00CHF 200.00n/a15
Dec ’24CHF 255.80
CHF 259.75
+1.5%
13.4%CHF 340.00CHF 200.00n/a16
Nov ’24CHF 217.30
CHF 249.50
+14.8%
15.8%CHF 340.00CHF 195.00CHF 320.8016
Oct ’24CHF 217.70
CHF 252.81
+16.1%
16.3%CHF 340.00CHF 195.00CHF 301.1016
Sep ’24CHF 233.10
CHF 253.59
+8.8%
15.4%CHF 331.00CHF 195.00CHF 295.8017
Aug ’24CHF 242.50
CHF 253.59
+4.6%
15.4%CHF 331.00CHF 195.00CHF 269.3017
Jul ’24CHF 238.20
CHF 254.76
+7.0%
14.8%CHF 331.00CHF 195.00CHF 280.3017
Jun ’24CHF 235.70
CHF 248.91
+5.6%
14.6%CHF 320.00CHF 180.30CHF 284.8018
May ’24CHF 281.80
CHF 257.58
-8.6%
15.1%CHF 330.00CHF 180.30CHF 255.4016
Apr ’24CHF 268.60
CHF 257.33
-4.2%
15.2%CHF 330.00CHF 180.30CHF 261.1016
Mar ’24CHF 231.40
CHF 258.71
+11.8%
15.4%CHF 330.00CHF 180.30CHF 276.5016
Feb ’24CHF 233.40
CHF 258.71
+10.8%
15.4%CHF 330.00CHF 180.30CHF 279.1016
Jan ’24CHF 219.30
CHF 286.21
+30.5%
20.7%CHF 450.00CHF 180.30CHF 274.4016
Dec ’23CHF 248.10
CHF 291.29
+17.4%
20.0%CHF 450.00CHF 180.30CHF 255.8015
Nov ’23CHF 234.80
CHF 305.21
+30.0%
16.9%CHF 450.00CHF 255.00CHF 217.3014

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Ascom Holding

CHF 155.7m

Provides healthcare ICT and mobile workflow solutions worldwide.

ASCN

CHF 4.21

7D

-5.1%

1Y

-56.6%

Becton Dickinson

US$66.7b

Develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.

912061

US$238.02

7D

0%

1Y

-2.2%

Galenica

CHF 3.8b

Operates as a healthcare service provider in Switzerland and internationally.

GALE

CHF 75.90

7D

0.2%

1Y

7.2%